Nirsevimab Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix AusVaxSafety has been conducting active safety surveillance of Beyfortus (nirsevimab) – a new long-acting injectable monoclonal antibody product used for the prevention of severe respiratory syncytial virus (RSV) disease in infants – at participating sites in New South Wales and Queensland throughout the 2024 winter season.In Australia, nirsevimab is currently only available to infants and young children through state-managed programs in New South Wales, Queensland and Western Australia.Safety data are gathered via surveys sent to recipients in the days following nirsevimab administration.The Western Australia RSV immunisation program also includes active safety surveillance, with reports published through Government of Western Australia Department of Health channels.Surveillance of nirsevimab is underway. This page will be updated once enough data to enable meaningful analysis is collected by AusVaxSafety. Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix News & events All news & events 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change 03 June 2025 | News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations 18 May 2025 | News 2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination 31 March 2025 | News AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines